Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.35 |
| ▸ | CSF1R | P07333 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24433598 | 0.87 | HTR7 (0.40) | HTR7HTR1AAOC3CSF1RFFAR1 | |
| SCHEMBL14868787 | 0.81 | AOC3 (0.47) | AOC3ESR1ESR2ROCK1TAAR1 | |
| SCHEMBL14869007 | 0.78 | PIM1 (0.48) | AOC3CSF1REGFR | |
| SCHEMBL14868870 | 0.75 | DRD2 (0.46) | HTR1ABACE1TAAR1 | |
| SCHEMBL14339693 | 0.74 | PYCR1 (0.45) | AOC3TAAR1 | |
| SCHEMBL19164539 | 0.74 | DRD2 (0.37) | CSF1RTAAR1 | |
| SCHEMBL14869158 | 0.74 | DRD2 (0.44) | TAAR1 | |
| SCHEMBL14869312 | 0.74 | TSHR (0.40) | TAAR1 | |
| SCHEMBL14868818 | 0.73 | AOC3 (0.50) | HTR1AAOC3TAAR1 | |
| SCHEMBL14872445 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | HTR7 1175/4885HTR1A 2011/4885AOC3 2957/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | HTR7 1175/4885HTR1A 2011/4885AOC3 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.